Teva Pharmaceutical Industries (TEVA) Receives a Buy from Raymond James
In a report released today, Elliot Wilbur from Raymond James maintained a Buy rating on Teva Pharmaceutical Industries (TEVA). The company’s shares closed last Monday at $9.29.
According to TipRanks.com, Wilbur ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.0% and a 41.7% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Flexion Therapeutics, and Sol-Gel Technologies.
The word on The Street in general, suggests a Hold analyst consensus rating for Teva Pharmaceutical Industries with a $12.20 average price target, which is a 30.5% upside from current levels. In a report issued on October 13, Argus Research also maintained a Buy rating on the stock with a $11.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.76 and a one-year low of $6.25. Currently, Teva Pharmaceutical Industries has an average volume of 8.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Read More on TEVA: